Related Experiment Video
Updated: Mar 6, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Estimation and Characterization of Adverse Drug Reactions Induced by Immunomodulators in Connective Tissue Disorders:
Chaitali A Chindhalore1, Sanjaya Dhal1, Ganesh N Dakhale1
1Department of Pharmacology, All India Institute of Medical Sciences, Nagpur, Maharashtra, India.
Background:
Immunomodulators are foundational in managing connective tissue disorders connective tissue disorders (CTDs) but can produce significant adverse drug reactions (ADRs) that might affect adherence and outcomes.
Methodology:
A cross-sectional observational study was conducted over 6 months at AIIMS Nagpur among adults with CTDs receiving immunomodulators for >1 month. Standard causality (World Health Organization/Uppsala Monitoring Center [WHO-UMC], Naranjo), severity (Hartwig-Siegel), and preventability (Schumock-Thornton) scales were applied and associations were assessed using the Chi-square test.
Results:
Among 105 patients (mean age 42.68 ± 15.55 years; 76.2% female), 19 ADRs were identified. Drugs most implicated included prednisolone, methotrexate, and hydroxychloroquine, with typical events such as central serous retinopathy, hypertension, oral ulcers, and rashes. Causality was mostly probable by WHO-UMC (71.4%) and Naranjo (57.9%); severity was mild-to-moderate (89.5%); preventability was mostly probable (84.2%); no life-threatening outcomes occurred, and 73.7% recovered fully by last follow-up. No significant associations were found between ADR occurrence and sex, age group, or comorbidity status (all P > 0.05).
Conclusion:
In CTDs, immunomodulator-related ADRs were predominantly probable, mild-to-moderate, and largely preventable. Routine monitoring and patient counseling can reduce avoidable harm.
More Related Videos
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug Toxicity: Allergic Reactions
Allergic Drug Reactions
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drug Toxicity: Risk factors